U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H15F3N4O3
Molecular Weight 404.3433
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOSUFLOXACIN

SMILES

c1cc(c(cc1F)F)-n2cc(c(=O)c3cc(c(nc32)N4CCC(C4)N)F)C(=O)O

InChI

InChIKey=WUWFMDMBOJLQIV-UHFFFAOYSA-N
InChI=1S/C19H15F3N4O3/c20-9-1-2-15(13(21)5-9)26-8-12(19(28)29)16(27)11-6-14(22)18(24-17(11)26)25-4-3-10(23)7-25/h1-2,5-6,8,10H,3-4,7,23H2,(H,28,29)

HIDE SMILES / InChI

Description
Curator's Comment:: http://medical.taishotoyama.co.jp/data/if/pdf/ozx.pdf

Tosufloxacin is a fluoroquinolone antibacterial agent. Tosufloxacin is an inhibitor of bacterial DNA gyrase and topoisomerase IV. Tosufloxacin is indicated for the treatment of various infections such as skin, respiratory, urinary, gynecologic, ophthalmologic, otolaryngologic, dental infections. Fluoroquinolones including tosufloxacin have a potential risk of inducing cartilage and joint toxicity in children. It is also associated with severe thrombocytopenia and nephritis, and hepatotoxicity.

CNS Activity

Curator's Comment:: Known to be CNS penetrant in rats. Human data not available.

Originator

Curator's Comment:: http://adisinsight.springer.com/drugs/800005704 | http://www.chemdrug.com/article/8/3285/16420748.html

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Ozex

Approved Use

It is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections.

Launch Date

632966400000
Curative
Ozex

Approved Use

It is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections.

Launch Date

632966400000
Curative
Ozex

Approved Use

It is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections.

Launch Date

664502400000
Curative
Ozex

Approved Use

It is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections.

Launch Date

632966400000
PubMed

PubMed

TitleDatePubMed
Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
1993 Apr
In-vitro activity of quinolones and macrolides against mycobacteria.
1994 Sep
Trovafloxacin is active against Toxoplasma gondii.
1996 Aug
Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
1996 Dec
N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies.
1996 Nov
Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position.
1996 Oct
[In vitro anti-MAC activities of new quinolones in focus (2)].
1996 Sep
The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors.
2000 Jul
History of quinolones and their side effects.
2001
Evaluation of in-vitro and in-vivo antibacterial activity of tosufloxacin tosilate.
2001 Dec
Effect of hydrophobicity and molecular mass on the accumulation of fluoroquinolones by Staphylococcus aureus.
2001 Mar
In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species.
2002 Mar
Possible involvement of P-glycoprotein in the biliary excretion of grepafloxacin.
2002 Mar
In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.
2002 Mar
[The history of the development and changes of quinolone antibacterial agents].
2003
[Salmonella infections].
2003 Feb
Alteration of constitutive apoptosis in neutrophils by quinolones.
2003 Jun
Anaphylaxis due to tosufloxacin tosilate.
2003 Sep
Pharmacokinetic-pharmacodynamic analysis of fluoroquinolones against Bacillus anthracis.
2004 Apr
Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.
2004 Apr
In vitro activity of pazufloxacin, tosufloxacin and other quinolones against Legionella species.
2005 Dec
VapB-positive Rhodococcus equi infection in an HIV-infected patient in Japan.
2005 Feb
In vitro activity of fluoroquinolones against Mycoplasma genitalium and their bacteriological efficacy for treatment of M. genitalium-positive nongonococcal urethritis in men.
2005 Nov 1
[Successful treatment with voriconazole for disseminated cutaneous and visceral infection by Fusarium solani in a patient with acute myeloid leukemia].
2006 Aug
[Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae AND Haemophilus influenzae with the use of Monte Carlo simulation].
2006 Dec
[Antibacterial activity of tosufloxacin against major organisms detected from patients with respiratory infections].
2007 Apr
[Effectiveness of switch therapy for peritonitis].
2007 Aug
A novel in vivo rabbit model that mimics human dosing to determine the distribution of antibiotics in ocular tissues.
2007 Aug
Multidrug-resistant typhoid fever outbreak in travelers returning from Bangladesh.
2007 Dec
[A case of acute bronchitis caused by Neisseria meningitidis associated with HIV infection].
2007 Nov
Effect of GrlA mutation on the development of quinolone resistance in Staphylococcus aureus in an in vitro pharmacokinetic model.
2007 Nov
[Sensitivity surveillance of Haemophilus influenzae isolates for several antibiotics in Gifu Prefecture (2006)].
2008 Aug
Antibiotic prophylaxis for transrectal prostate biopsy: a prospective randomized study of tosufloxacin versus levofloxacin.
2008 Jul
Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones.
2008 Jun
In vitro susceptibilities of bacterial isolates from conjunctival flora to gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin.
2008 Mar
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
2009
Fluoroquinolones reduce carrageenan-induced edema in rats and the involvement of the glucocorticoid receptor system.
2009 Apr
Measurement of AQCmax of five different ophthalmic solutions and discussion of its new application.
2009 Aug
Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles.
2009 Dec 2
Corneal deposits after topical tosufloxacin in a patient with poor tear secretion.
2009 Jan
[Antibacterial activity of quinolones against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].
2009 Jun
Levofloxacin 0.5% ophthalmic solution: a review of its use in the treatment of external ocular infections and in intraocular surgery.
2009 Jun 18
[Efficacy of tosufloxacin in genital chlamydial infections].
2009 Oct
Antituberculosis activity of the molecular libraries screening center network library.
2009 Sep
[Intractable pediatric infectious disease: examining the ability of a new drug, tosufloxacin tosilate hydrate for pediatric].
2010 Dec
[Antibiotic susceptibility of blood-borne Streptococcus pneumoniae and efficacy assessment of respiratory quinolones using Monte Carlo simulation].
2010 Feb
[Epidemiological analysis of Streptococcus pneumoniae in Gifu prefecture].
2010 Jun
Risk factors for acute prostatitis after transrectal biopsy of the prostate.
2010 Jun
Legionella pneumophila induces cathepsin B-dependent necrotic cell death with releasing high mobility group box1 in macrophages.
2010 Nov 22
Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines.
2010 Sep 20
Patents

Sample Use Guides

In general, for adults, take 2 to 3 tablets (300 to 450 mg of the active ingredient) a day, in 2 to 3 divided doses. The dosage may be adjusted according to disease, symptoms, etc. of the patient. If symptoms are severe or the effect is insufficient, take 4 tablets (600 mg) a day.
Route of Administration: Oral
The MIC90s of tosufloxacin among the 27 isolates of macrolide-resistant Mycoplasma pneumoniae (MRMP) was 0.25 ug/ml and those among the 23 isolates of macrolide-sensitive Mycoplasma pneumoniae (MSMP) was 0.5 μg/ml.
Name Type Language
TOSUFLOXACIN
INN   MART.   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
A 67107
Code English
ABBOTT-61827
Code English
TOSUFLOXACIN [INN]
Common Name English
ABBOTT 61827
Code English
1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, 7-(3-AMINO-1-PYRROLIDINYL)-1-(2,4-DIFLUOROPHENYL)-6-FLUORO-1,4-DIHYDRO-4-OXO-, (+/-)-
Common Name English
TOSUFLOXACIN [MI]
Common Name English
(+/-)-7-(3-AMINO-1-PYRROLIDINYL)-1-(2,4-DIFLUOROPHENYL)-6-FLUORO-1,4-DIHYDRO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID
Systematic Name English
TOSUFLOXACIN [MART.]
Common Name English
TOSUFLOXACIN [USAN]
Common Name English
A 61827
Code English
TOSUFLOXACIN [WHO-DD]
Common Name English
A-67107
Code English
A-61827
Code English
Classification Tree Code System Code
WHO-ATC J01MA22
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
NCI_THESAURUS C795
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
Code System Code Type Description
EPA CompTox
100490-36-6
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY
ChEMBL
CHEMBL273348
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY
DRUG CENTRAL
2710
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY
INN
6242
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY
EVMPD
SUB11201MIG
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY
NCI_THESAURUS
C80642
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY
WIKIPEDIA
TOSUFLOXACIN
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY
CAS
100490-36-6
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY
FDA UNII
GHJ553KQPS
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY
MERCK INDEX
M10984
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY Merck Index
PUBCHEM
5517
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY